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Targeting the tumor stroma in addition to the  malignant 
cell compartment is of paramount importance to achieve 
complete tumor regression. In this work, we modified a 
previously designed tumor stroma-targeted condition-
ally replicative adenovirus (CRAd) based on the SPARC 
promoter by introducing a mutated E1A unable to 
bind pRB and pseudotyped with a chimeric Ad5/3 fiber 
(Ad F512v1), and assessed its replication/lytic capacity in 
ovary cancer in vitro and in vivo. AdF512v1 was able to 
replicate in fresh samples obtained from patients: (i) with 
primary human ovary cancer; (ii) that underwent neoad-
juvant treatment; (iii) with metastatic disease. In addi-
tion, we show that four intraperitoneal (i.p.) injections 
of 5 × 1010 v.p. eliminated 50% of xenografted human 
ovary tumors disseminated in nude mice. Moreover, 
AdF512v1 replication in tumor models was enhanced 
15–40-fold when the tumor contained a mix of malig-
nant and SPARC-expressing stromal cells (fibroblasts 
and endothelial cells). Contrary to the wild-type virus, 
AdF512v1 was unable to replicate in normal human 
ovary samples while the wild-type virus can replicate. 
This study provides evidence on the lytic capacity of this 
CRAd and highlights the importance of targeting the 
stromal tissue in addition to the malignant cell compart-
ment to achieve tumor regression.
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publication 4 September 2012. doi:10.1038/mt.2012.147
IntroductIon
Ovarian cancer is one of the leading gynecologic malignancies 
globally; Scandinavia, Israel, and North America have the highest 
rates of incidence (10–15/100,000) while developing countries 
and Japan exhibit the lowest incidence (5/100,000).1–3 Although 
progress in conventional therapies (surgery, chemotherapy, and 
irradiation) has been achieved, the 5-year survival rate for patients 
with advanced stage ovarian cancer is still low.3
One of the potential approaches to tackle the advanced stages 
of the disease is the use of conditionally replicative adenoviruses 
(CRAds).4 Several oncolytic adenoviruses, including few CRAds, 
were assessed in ovary cancer models following grafting of human 
cells in immunodeficient mice.5–7 Different CRAds whose repli-
cation was driven by the promoters corresponding to VEGF,5 
Cox-2,8 the leukoprotease inhibitor,9 CXCR4, Survivin, and 
Mesothelin6 also exhibited important therapeutic efficacy on dis-
seminated ovarian cancer models and extended mice survival, but 
none of them was reported to be able to eliminate disseminated 
tumors.5,6,8,9 In all cases, the target of the viruses was the malignant 
epithelium with no specific consideration on the capacity of the 
viruses to target the stromal cell compartment. The nonreplicative 
adenovirus Ad5.SSTR/TK.RGD where gene expression is driven 
by an immediate-early CMV promoter,10 the E1B-55kd gene 
deleted oncolytic adenovirus ONYX-015 with no specificity for 
ovarian cancer,11 and the CRAd Ad5-Δ24RGD,12 entered clinical 
trials. Despite the lack of partial or complete responses the trials 
highlighted the feasibility and safety of oncolytic adenoviruses use 
in the clinics, and reinforced the need to enhance viral replication 
and specificity.
Recent studies have shown that most aggressive ovarian can-
cer, especially those disseminated in the peritoneum and the 
omentum, exhibited a high content of genes expressed by stromal 
cells.13 Stringent follow up studies demonstrated that patients with 
tumors showing enhanced activity of stromal genes exhibited the 
poorest survival.13 Type I and III collagen produced by the tumor 
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stroma were proposed as predictors of poor outcome in human 
ovarian cancer.14 Thus, novel approaches based on medicines that 
target the tumor stroma compartment can be highly effective in 
elusive tumors such as advanced ovarian cancer.
SPARC (secreted protein, acidic, rich in cysteine) is a secreted 
glycoprotein that has been associated with most aggressive human 
cancers.15,16 Elevated immunostaining was observed in 40–80% of 
human malignant ovarian carcinomas.17–19 Interestingly, SPARC 
was mainly expressed in the tumor stroma, including endothelial 
cells and fibroblasts, in close contact with the leading edge of the 
tumor; in addition, almost 15% of ovary carcinomas exhibited 
SPARC expression in epithelial cells;17 however, in situ hybridization 
showed no SPARC reactivity in malignant ovary epithelial cells sug-
gesting that in most cases SPARC is secreted by stromal fibroblasts 
and internalized by epithelial cells at the tumor-stromal interface.20 
It appears that SPARC expression is downregulated in several types 
of epithelial cancer cells due to promoter methylation.21
With the aim of targeting the stromal compartment of the 
tumor mass, we have previously designed a CRAd based on a spe-
cific fragment of the SPARC promoter (Ad-F512). Ad-F512 was 
also active on pancreatic cancer cells with silenced SPARC expres-
sion due to promoter methylation; however, Ad-F512 efficacy was 
greatly dependent on the presence of the accompanying stromal 
cells both in xenografted human melanoma and pancreatic can-
cer models.22 Here, we demonstrate a strong therapeutic effect of 
an improved version of Ad-F512 (named AdF512v1), where the 
F512-SPARC promoter drives the expression of E1A mutated in 
one of the pRb-binding sites, and the CRAd was pseudotyped 
with a chimeric fiber Ad5/3. We show that AdF512v1 replicated 
in fresh tissue explants obtained from ovarian cancer patients that 
received or not neoadjuvant chemotherapy and in disseminated 
tumors, but exhibited no replication in nonmalignant human 
ovary tissue explants; AdF512v1 was also therapeutically effec-
tive in a human ovarian cancer model disseminated in the peri-
toneum and cured 50% of the mice. Moreover, AdF512v1 showed 
enhanced replication in vitro in ovary cancer xenografts that con-
tained human stromal cells holding promise regarding its poten-
tial utility in solid desmoplastic tumors.
results
In vitro activity of different versions of Ad-F512  
on ovary cancer cell lines
In previous studies, we observed that Ad-F512 was active both in 
human melanoma cells and certain pancreatic cancer cells lines 
regardless of SPARC mRNA levels.22 In order to assess whether 
the F512-SPARC promoter is active in epithelial ovary cancer cells 
we transduced three ovary cancer cell lines with nonreplicative 
adenoviral vectors pseudotyped or not with the chimeric fiber 
5/3 and expressing luciferase under the control of F512-SPARC. 
These studies confirmed that F512-SPARC was active in ovary 
cancer cells regardless of SPARC mRNA levels (Figure 1a and 
Supplementary Table S1). Moreover, F512-SPARC was as active 
as the SV40 promoter and the viral vector carrying the chimeric 
fiber 5/3 showed 2 to almost 80-fold—enhanced activity compared 
to the viral vector carrying the native type 5 fiber (Figure 1a).
Therefore, we decided to construct four novel versions of 
Ad-F512 pseudotyped with the chimeric fiber 5/3 and carrying 
different variants of mutated E1A that can restrict viral replica-
tion in nonmalignant tissue. AdF512v1 includes a deletion that 
restricts E1A binding to pRb; AdF512v2 includes an E1A dele-
tion that restricts its binding to p300 and AdF512v3 includes E1A 
mutated both in the pRB- and p300-binding sites; AdF512wt con-
tains the E1A wild type (Figure 1b). By reverse transcription-PCR 
analysis we observed that AdF512v1 and AdF512wt exhibited 
quite similar patterns of E1A RNA expression with the presence 
of five bands of different molecular weights; part of these bands 
were absent in AdF512v2 and AdF512v3 (Figure 1c); in coinci-
dence with the mRNA pattern, AdF512v1 and AdF512wt showed 
very similar E1A protein pattern, while AdF512v2 and the double 
mutant exhibited lower or faint levels respectively, of the highest 
molecular weight E1A band and the appearance of E1A bands of 
lower molecular weights (Figure 1d).
Based on the differences in E1A expression pattern at the mRNA 
and protein level between the different CRAds we decided to com-
pare their lytic capacity in four different ovary cancer cell lines. 
AdF512v1 exhibited the best lytic effect in all the cell lines assayed 
(Figure 2a–d). The percentage of remaining viable cells after infec-
tion with AdF512v1 (at multiplicity of infection (MOI) 100) was 
25, 8, 12, and 7% for OV-4, SKOV3.ip1, OVCAR-3, and PA-1 ovary 
cancer cells, respectively. At the lowest MOIs (0.1–10), Ad-wt 5/3 
was slightly more effective than AdF512v1 OV-4, OVCAR-3, and 
SKOV3.ip1 and more effective in PA-1 cells although at MOI 100 
both viruses exhibited a similar lytic effect. In order to confirm the 
lytic capacity of AdF512v1, we transduced three of the ovary cancer 
cell lines with AdF512v1 at MOI 100. We observed by flow cytometer 
analysis the absence of viable cells 4 days after infection confirming 
the lytic capacity of AdF512v1 on ovary cancer cells (Supplementary 
Figure S1). Ad-wt 5/3 was used as a control of cell lysis.
Ex vivo replication of AdF512v1 in fresh human ovary 
cancer explants
Instead of pursuing the comparison of the different CRAds only 
in terms of their in vitro lytic capacity on malignant cell lines, we 
decided to further explore their capacity to replicate ex vivo on 
freshly available tumor explants. The use of these explants is becom-
ing a valuable tool to assess viral replication since they resemble the 
situation CRAds face in the clinics. The explants used in the pres-
ent studies exhibited epithelial cells nests intermingled in abundant 
stroma containing mainly fibroblasts and some endothelial vessels 
that exhibited intense SPARC staining (Supplementary Figure 
S2a). Freshly available explants were obtained from patients under-
going surgery due to a primary or metastatic ovarian carcinoma; 
normal ovary samples were obtained from patients undergoing 
surgery for other pathologies and expressed faint levels of SPARC 
(Supplementary Figure S2b). Initial samples transduced with the 
nonreplicative Ad-F512(Luc 5/3) confirmed that F512-SPARC was 
at least 10-times more active in the ovary cancer explants than in 
normal ovaries (Supplementary Figure S2c). CRAds replication 
was evaluated in explants obtained from 13 patients. Samples were 
infected at ~500 v.p./cell of the different Ad-F512 versions, and 
compared to Ad-wt 5/3. In preliminary studies we determined that 
the best time for E4 assessment as a surrogate marker of viral rep-
lication is 72 hours after infection (data not shown). We analyzed 
samples from 4 primary tumors obtained from untreated patients, 5 
Molecular Therapy 3
© The American Society of Gene & Cell Therapy
CRAd Activity in Human Ovarian Cancer Models
primary tumors from 4 patients with previous chemotherapy, 4 met-
astatic samples obtained from 2 patients and 5 normal ovary sam-
ples. AdF512v1 was the only CRAd that replicated in ovary cancer 
samples 7, 10, and 13 (Figure 3a, c and d). Interestingly, AdF512v1, 
that we confirmed was unable to bind pRb (Supplementary Figure 
S3), did not replicate in normal ovary explants obtained from 
postmenopausal patients 5, 11, 12, 13, and 17 (Figures 3d and 4). 
Interestingly, none of the novel CRAds-containing mutated E1A 
was able to replicate in the malignant explants (Figure 3).
In further studies, we were able to evaluate AdF512v1 replica-
tion in samples from patients that ended paclitaxel and carbopla-
tin neoadjuvant chemotherapy 1 month before surgery (samples 
14, 15, 16, and 19, Figure 5); in two cases (samples 15 and 16) we 
also included disseminated tumor tissue obtained from different 
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Figure 1 F512-sPArc promoter activity in ovary cancer cells. (a) Luciferase activity of F512-SPARC and SV40 promoters in three ovary cancer 
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regions of the peritoneal cavity and in case 14 we also obtained 
a sample from a nonmalignant ovary (Figure 5). AdF512v1 sig-
nificantly replicated in malignant samples obtained from intestine 
and liver metastasis indicating that remnant cells after neoadjuvant 
chemotherapy are sensitive to the CRAd lytic activity (Figure 5). 
Histological analyses confirmed that remnant malignant cells were 
viable with no evidence of necrotic cells (data not shown). With 
the exception of cancer sample 14 and normal sample 17, Ad-wt 
5/3 could replicate in all samples regardless of whether they were 
cancer or noncancer ovary tissue (Figures 3–5). Interestingly, the 
replication rates of AdF512v1 were superior to Ad-wt 5/3 in can-
cer samples 7, 10, and 19; Ad-wt 5/3 replication increased sixfold 
at 72 hours in patient 7, whereas AdF512v1 replication increased 
100-fold at the same time point. In patient 10, we observed six-
fold increase with Ad-wt 5/3 and 46-fold increased replication 
with AdF512v1, while in patient 19 was 40 and 714, respectively 
(Figures 3a,c and 5d, and Supplementary Table S2). Mostly 
important, with the exception of a slight replication in sample 18, 
AdF512v1 was essentially unable to replicate in normal ovary tis-
sue. Thus, the overall ex vivo data with human samples prompted 
us to select AdF512v1 to further in vivo studies in animal models 
of disseminated solid human ovary cancer.
In vivo studies with AdF512v1
Therapeutic efficacy on a disseminated xenograft model. To 
further assess the in vivo therapeutic efficacy of AdF512v1 we 
injected 3 × 106 luciferase-expressing SKOV3-luc ovary cancer 
cells in female nude mice peritoneum. Carcinomatosis developed 
in 6 days when visible tumors were observed. Treatment was ini-
tiated the next day by administering 4 injections intraperitoneal 
(i.p.) of 5 × 1010 v.p./400 μl of virus or control vehicle every other 
day (Figure 6a). Tumor growth was evaluated in two independent 
experiments by bioluminescent imaging follow up at days 9, 23, 
and 30 after the initiation of AdF512v1 administration (Figure 6b 
and c). In one experiment, we also included the parental CRAd 
Ad-F512 as an additional control. By day 30 mice were sacrificed 
and the number and weight of metastases was determined. We 
observed a strong increase in the luminescence signal in con-
trol and Ad-F512-treated animals whereas in mice treated with 
AdF512v1 the signal intensity was strongly inhibited (Figure 6b 
and c). In fact, we were unable to detect luminescence signal in 
1/5 (first experiment) and 3/6 (second experiment) AdF512v1-
treated mice indicating tumor absence. Macroscopic and micro-
scopic examination of the peritoneal cavity at autopsy revealed no 
evidence of viable tumor tissue in cured mice while control mice 
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Figure 2 conditionally replicative adenovirus (crAd) activity in ovary cancer cells. (a–d) Correspond to ovarian cancer cell lines OV-4, SKOV3.
ip1, OVCAR-3, and PA-1. Oncolytic capacity of the CRAds. Six days postinfection cell viability was assessed quantitatively using the MTS assay. Data 
was normalized to uninfected cells. Error bars represent the mean ± SEM (n = 3). 
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showed areas of luminescence emission confirmed as micrometas-
tases in spleen, diaphragm and pancreas (Supplementary Figure 
S4a). Quantification of visible metastases revealed an average of 
4 metastatic foci in control mice, 3 metastatic foci in Ad-F512-
treated mice while mice treated with AdF512v1 showed none or 
a maximum of 1 metastatic nodule per mice in both experiments 
(Supplementary Figures S4b and c). Similar differences between 
AdF512v1-treated and control or Ad-F512-treated mice were 
observed when the weight of the metastatic mass was compared 
(Supplementary Figures S4d and e). Although, AdF512v1 was not 
designed for systemic use we established its efficacy on this model 
of disseminated cancer after intravenous administration through 
the tail vein. No therapeutic effect was observed with a single 
administration of 1010 v.p. of AdF512v1 administered 7 days after 
SKOV3-luc ovary cancer cells injection (Supplementary Figure 
S5a). In a second experiment mice were administered twice with 
the CRAds with 1 week difference, and despite the fact that we 
have not seen statistical differences (Supplementary Figure S5b), 
1/5 mice treated with AdF512v1 exhibited a visible reduction in 
the tumor mass (Supplementary Figure S5c).
Viral retention in the tumor niche
Based on the previous in vivo data, our next aim was to estab-
lish whether differential CRAd retention at the tumor niche 
was associated with the in vivo therapeutic effect. Initially, we 
injected i.p. 5 × 1010 v.p. of Ad-F512(Luc-5/3) in healthy mice 
and 48 hours later we observed considerable luciferase activity 
restricted mainly to the liver and to a lesser extent to the spleen 
and gonads (Figure 7a). The other organs showed negligible 
luciferase expression. Next, we grafted mice with SKOV3-luc 
ovary cancer cells followed by AdF512v1 administration once 
i.p. at day 7 and removed tumor, liver, and spleen 5 hours, 1, 
3, 4, and 18 days post-AdF512v1 injection to establish viral 
retention by the different organs; gonads were discarded in this 
initial experiment due to the presence of infiltrating malignant 
cells that were detected own to the routine luminescence analy-
sis performed to avoid contamination by infiltrating malignant 
cells. We observed that the tumor mass was very efficiently 
infected since there were 10–16 more AdF512v1 particles in 
tumor samples at 5 hours and at day 1 compared to liver and 
spleen (Figure 7b). In addition, no viral particles were retained 
in liver and spleen by day 18 whereas the tumor showed the 
presence of almost 500 E4 copies per ng of DNA (Figure 7b). 
In a second experiment viral particles were evaluated at days 
1 and 18 and once more we observed that AdF512v1 retention 
by the tumor was very high compared to the normal organs 
(Figure 7c). Interestingly, AdF512v1 levels in tumor-infiltrated 
gonads at 18 days was 250-fold higher than the levels in tumor-
free gonads indicating that the virus targets and is retained pref-
erentially by the tumor niche (Figure 7c).
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Figure 3 Viral replication in freshly excised human ovary cancer explants. (a–d) Correspond to samples obtained from patients with primary 
ovary cancer. Human ovary cancer explants were infected with 500 v.p./cell of the different viruses and after 5 or 72 hours samples were collected 
and DNA was isolated. E4 levels were determined by real-time PCR. Levels of E4 at 72 hours were normalized with the data at 5 hours. Sample 13 also 
includes the contralateral normal ovary. Error bars represent the mean ± SEM, n = 3 for each sample. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Ex vivo and in vivo effect of AdF512v1 on tumors 
composed of malignant and stromal cells
The previous data demonstrated that AdF512v1 is a more potent 
version of Ad-F512 that was designed to target both the malignant 
and the stromal compartment of the tumor mass. Human adeno-
viruses such as AdF512v1 do not replicate in murine stromal cells 
that are recruited to the growing human ovary tumor xenograft. 
Therefore, we performed a series of experiments to establish the 
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Figure 4 Viral replication in explants of nonmalignant human ovary explants. (a–e) Correspond to samples obtained from patients with normal 
ovary. Nonmalignant ovary samples were analyzed as described in Figure 3. Error bars represent the mean ± SEM, n = 3 for each sample. *P < 0.05.
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Figure 7 AdF512v1 retention at different organs. (a) Naive mice were intraperitoneal (i.p.) injected once with Ad-F512 (Luc 5/3) and 48 hours 
later the main organs were collected and luciferase activity was assayed. Results are presented as relative light units (RLU) normalized for total pro-
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relevance of the stromal cell component on AdF512v1 thera-
peutic efficacy. In initial experiments we observed that human 
fetal fibroblasts WI-38 that exhibit characteristics that resemble 
cancer-associated fibroblasts, and transformed-microendothelial 
cells (HMEC-1) could support replication of AdF512v1 that can 
lyse these type of stromal cells (Supplementary Figure S6). In 
a second series of experiments we plated (ratio 1:1:1) a mix of 
SKOV3-luc ovary cancer cells, WI-38 fibroblasts and HMEC-1 
transformed-microendothelial cells previously infected or not 
with AdF512v1 and evaluated total cell viability with MTS and 
viable SKOV3-luc cells through luciferase expression. The stron-
gest in vitro lytic effect (both by MTS and luciferase expression) 
was observed when the three cell types were previously infected 
with AdF512v1 (Figure 8a and Supplementary Table S3 and 
Supplementary Figure S7). Moreover, previous infection of 
stromal cells, once at a time, with AdF512v1, led to significant 
reduction in the amount of remaining viable cells and to almost 
the complete elimination of SKOV3-luc cells, suggesting that 
stromal cells supported viral replication and spreading that led 
to the elimination of coplated ovary cancer cells (Figure 8a and 
Supplementary Table S3).
To further assess the involvement of the stromal compart-
ment in viral efficacy, we established SKOV3-luc subcutaneous 
tumors in nude mice combined or not with a mix of HMEC-1 
and WI-38 cells. When tumors reached 500 mm3 animals were 
sacrificed and tumor explants were ex vivo treated and infected 
as described for human tumor samples. We observed that 
mixed tumors containing ovary cancer and stromal cells were 
infected with less efficiency than tumors without stromal cells 
(see E4 copy number levels at 5 hours postinfection, Figure 8b). 
Ad-wt 5/3 replication at 72 hours was marginally affected by the 
presence of stromal cells (Figure 8b). Interestingly, AdF512v1 
showed increased rates of replication in tumors containing 
stromal cells clearly suggesting that stromal cells can enhance 
viral replication leading to increased lytic activity (Figure 8b). 
Interestingly, similar experiments performed with another 
ovary cancer cell line PA-1 that express SPARC but was less sen-
sitive to AdF512v1 lytic effect than SKOV3 cells, also showed 
an improvement in viral replication in the presence of stromal 
cells (Supplementary Figure S8). In fact both Ad-wt 5/3 and 
AdF512v1 were unable to replicate in tumors made of cancer 
cells alone (Supplementary Figure S8) indicating that stromal 
cells play a relevant role probably by supporting viral replica-
tion and secreting soluble factors that rendered malignant cells 
more sensitive to the virus.22
We finally established the therapeutic efficacy in vivo of 
AdF512v1 on tumors made of SKOV3-luc cells mixed with WI-38 
and HMEC-1 cells. The cells mix was implanted subcutaneous for 
the clear limitation of injecting the mix directly into the perito-
neum. Once tumors reached 100 mm3 we treated mice with three 
intratumor administrations of AdF512v1, Ad-F512 or phosphate-
buffered saline (PBS) (at days 0, 3, and 7). At the end of the experi-
ment one of three mice treated with AdF512v1 was completely 
free of tumor and the other two showed greatly reduced tumor 
volumes compared to the group of mice treated with Ad-F512 or 
PBS. The differences between the AdF512v1-treated group and 
the other two groups were statistically significant (Figure 8c and 
Supplementary Figure S9).
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Figure 8 Ex vivo replication and in vivo antitumor effect of AdF512v1 on tumor xenografts composed of malignant and stromal cells. 
(a) MTS assays after 6 days cocultures of SKOV3-luc (O), WI-38 fibroblasts (F), and HMEC-1 endothelial cells (E) previously infected (v) or not with 
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with AdF512v1 or Ad-wt 5/3 and after 5 or 72 hours DNA samples were isolated and E4 levels were determined by real-time-PCR. Fold of increment 
between 5 and 72 hours are shown between bars. Error bars represent the mean ± SEM (n = 3 or 4). (c) In vivo growth of subcutaneous tumors made 
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dIscussIon
According to Globocan data base more than 200,000 cases of 
ovarian cancer are diagnosed each year. It is estimated that more 
than 125,000 women with ovarian cancer die each year. The most 
important determination of survival seems to be disease stage at 
diagnosis. Only ~20% of women are diagnosed at an early stage, 
but in most of the cases the disease is detected at an advanced 
stage leading to a poor prognosis.2,23 Early disease stage has a 
5-year survival rate of greater than 70%, but for those diagnosed 
with advanced disease stage, it is below 15%. Currently available 
methods prove quite unable to detect ovarian cancer at an early 
stage,24 therefore new therapeutic tools are urgently needed.
Here, we characterized a novel CRAd that has been designed 
to target the tumor-associated stromal cell compartment since 
its replication is driven by a promoter fragment of the stroma-
 associated gene SPARC. We showed here that this novel CRAd 
was therapeutically effective in a xenograft model of dissemi-
nated/metastatic human ovary cancer inducing a major growth 
inhibitory effect including the complete remission of the tumor 
in 50% of the cases. Mostly important, this novel CRAd was also 
capable of replicate ex vivo in explants of fresh samples of primary 
human ovary cancer, obtained from patients that underwent or 
not neoadjuvant chemotherapy, and in ovary cancer metastases; 
but contrary to the wild-type virus it was almost unable to repli-
cate in noncancerous ovary samples. This oncolytic virus was able 
to replicate ex vivo and eliminate in vivo tumors made of malig-
nant and stromal cells.
Initial uses of oncolytic viruses for therapeutically targeting 
ovarian cancers involved the use of ONYX-15 an oncolytic virus 
with broad cancer spectrum and nonselective replication capac-
ity.11 The limited success of these initial trials was attributed at 
least in part to the reduced infective capacity of type 5 adenovi-
ruses that entered cells through CAR receptor.11 In a second study, 
a replicative-competent Edmonston B measless vaccine strain 
that infects cells through CD46 was administered to patients with 
recurrent ovarian cancer.25 Fourteen of the 21 patients exhibited 
stable disease and CA-125 levels were reduced by >30% in 5 of the 
21 patients.25 A more recent trial in recurrent malignant gyneco-
logic diseases including ovarian cancer has been published.12 This 
trial was based on an infectivity enhanced-oncolytic adenovirus 
carrying E1A mutated in the Rb-binding site whose transcriptional 
regulation was under the control of the wild-type promoter and 
the viral fiber was pseudotyped with an RGD motive to enhance 
viral infectivity. The authors found no severe adverse effect, and 
although no partial or complete responses were observed after 1 
month follow up, reduced CA-125 levels were observed in 7 of 21 
patients.12
AdF512v1 is an improved version of Ad-F512 that was shown 
to inhibit melanoma and pancreatic cancer growth in preclinical 
models.22 AdF512v1 was improved by (i) the incorporation of an 
insulator sequence upstrem of the F512-SPARC promoter, (ii) the 
incorporation of a mutated form of E1A unable to bind pRb, and 
(iii) virus pseudotyping with a chimeric 5/3 that binds preferen-
tially to type 3 adenoviral receptors. The decision to assess the 
therapeutic efficacy in ovarian cancer of AdF512v1 was due to the 
fact that SPARC is expressed mainly in stromal cells (fibroblasts 
and endothelial cells) in close contact with the forefront of the 
epithelial tumor mass.17,18 Interestingly, AdF512v1 was also able 
to replicate in ovarian cancer cells that express negligible SPARC 
levels. Silencing of SPARC expression in some epithelial ovarian 
cancer cells is mainly due to promoter methylation.17,20 As shown 
in previous studies, methylation of the internal promoter would 
not hinder the activity of the oncolytic virus provided the tran-
scription factors that regulate SPARC promoter activity are still 
expressed in the target cells.22
In addition to the use of a promoter active both in the malig-
nant and in the stromal cell compartment we decided to pseudo-
type the virus with a chimeric 5/3 fiber that retargets the virus 
to enter malignant cells through CD46, although recent evidence 
points to desmoglein as an additional receptor for type 3 adeno-
viral fiber.26 We observed that vectors expressing the 5/3 chimeric 
fiber exhibited at least 40% increased infectivity and lytic effect 
on ovary cancer cells compared to the virus expressing the type 5 
fiber. This is consistent with previous evidence showing that the 
Ad5/3 chimera displays enhanced infectivity in ovary cancer cell 
lines and purified primary tumor cells (~10-fold).5,6,27,28 Recently, 
it was shown that a full serotype 3 CRAd was as useful as the 5/3 
pseudotype virus.29
Reduced binding of E1A to pRb and p300/CPB emerged 
as a strategy to limit adenoviral replication in normal cells.30 
Therefore, we decided to mutate E1A to eliminate its capacity to 
bind to either of the two proteins or to both of them. Indeed, we 
observed that with the sole exception of sample 18, AdF512v1 was 
completely unable to replicate in normal human ovary explants, 
while the wild-type virus replicated both in malignant and nor-
mal ovary explants. In addition to the almost complete abrogation 
of its replication capacity in fresh human normal ovary samples 
AdF512v1 was also unable to replicate in the permissive Syrian 
hamster organs (data not shown). Thus, it appears that mutation in 
the pRB-binding site restricted AdF512v1 capacity to replicate in 
normal ovaries and greatly attenuated its potential harmful effect 
on normal organs. On the other hand, we observed that AdF512v1 
exhibited an enhanced in vitro activity even at the lowest MOI 
of 1 to 10 and ex vivo activity in human ovary cancer explants. 
This enhanced lytic/replication capacity was in close coincidence 
with previous studies showing that CRAds carrying an E1A muta-
tion in the pRb-binding site might exhibit similar or even better 
lytic effect in vitro than CRAds carrying the E1Awt gene.30–32 It was 
hypothesized that in the absence of pRb-binding capacity, there is 
an augmented E1A transactivation function either because pRb 
sequestration no longer occurs due to the abrogation of E1A feed-
back inhibition, or a diminished E1A ubiquitination as a result of 
a decreased phosphorylation status.31
Fresh cancer explants are being increasingly used as a reliable 
tool to assess viral capacity to replicate and lyse ex vivo human 
samples that resemble the situation the virus might face in a clini-
cal setting. This methodology has been already used in few works 
to assess the replication and lytic capacity of CRAds in breast and 
ovary explants.33–36 Besides, ex vivo liver tissue slices were used 
to assess CRAd-mediated liver toxicity.6,35,37 However, we show 
for the first time that a CRAd such as AdF512v1 was also able to 
replicate in ovary cancer samples and metastatic tissue obtained 
from patients that underwent mainstay neoadjuvant chemother-
apy that included paclitaxel and carboplatin to reduce the tumor 
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mass and allow subsequent surgery. Microscopic examination 
confirmed no necrotic tissue in selected samples and high lev-
els of cells viability. Few studies have shown that paclitaxel can 
enhance the in vitro adenoviral activity either by increasing E1A 
levels or the expression of cell surface receptors for the virus.38,39 
More recently it was shown that CRAd treatment followed by 
paclitaxel triggered apoptotic cell death.40 Here, we show for the 
first time that a CRAd was able to replicate and lyse remnant cells 
that were resistant to mainstay chemotherapy indicating that viral 
therapy can be effective on cell clones that can override frontline 
chemotherapy.
Studies in nude mice with the nonreplicative version of 
AdF512v1 expressing the luciferase gene demonstrated that the 
main target organs were liver, spleen and gonads. Interestingly, 
necropsies of mice treated with AdF512v1 revealed no toxicity 
in liver, spleens and gonads. These data demonstrate that aden-
oviruses based on the chimeric 5/3 fiber exhibit a narrow spec-
trum of target organs and are less toxic than adenovirus type 5, 
as this serotype can infect at high levels lung, kidney, and prostate 
and was extremely toxic to the liver in animal models.41 Besides, 
AdF512v1was retained at the tumor mass and infiltrated gonads 
with greater avidity compared to liver, spleen, and non-infiltrated 
gonads suggesting that the tumor niche might create a favorable 
environment for AdF512v1 replication. In this context it must be 
pointed out that E4 levels in the tumor mass are underestimated 
due (i) to the fact that the study was performed after only one 
single administration of the virus and (ii) since we were unable 
to quantify viral particles released by the tumor mass to the 
peritoneum.42
Increasing evidence indicates the importance of stromal cells 
(such as fibroblasts and endothelial cells) in early relapse and 
overall survival in ovary cancer.13 Ovary cancer patients with a 
high stromal molecular signature had the poorest survival;7,13 
moreover, collagen levels have been linked to chemotherapy resis-
tant in ovary cancer.14,43 Ad-F512 was originally designed to target 
mainly, but not only, the stromal fibroblasts and endothelial cells 
with the understanding that both the stromal and malignant epi-
thelium compartments should be eliminated to achieve complete 
remission of tumors such as ovary cancer, with large desmoplas-
tic reaction. Since AdF512v1 replicated in WI-38 fetal fibroblasts 
and HMEC-1 microendothelial cells, we also evaluated viral rep-
lication in vitro on coplated malignant and stromal cells, and ex 
vivo and in vivo on explants and tumors, respectively, composed 
of a mix of malignant and stromal cells. Interestingly, the virus 
replicated (as assessed by E4 copy levels) at a better extent in the 
combined malignant/stromal tumors than in tumors composed 
of malignant cells alone, and greatly reduced the in vivo tumor 
growth of tumors composed of malignant and stromal cells sug-
gesting overall that stromal cells might enhance viral efficacy by 
supporting viral replication and spreading. Moreover, we have 
previously shown that stromal cells can enhance viral efficacy not 
only because they can act as a viral reservoir but also because they 
can release factors that promote cell entry in a cell cycle phase that 
is more permissive to viral lytic activity.22 Thus, assessing CRAds 
activity in mixed tumors composed of malignant and stromal cells 
and in human explants might be essential to predict the therapeu-
tic potential of oncolytic adenoviruses.
MAterIAls And Methods
Cell lines and cell culture. All the cells used in this work are described in 
the Supplementary Materials and Methods section.
Construction and production of adenoviruses. Adenoviruses were devel-
oped as described in the Supplementary Materials and Methods section 
by using homologous recombination in bacteria. Viral constructs were 
confirmed by restriction pattern and automatic DNA sequencing (ABI 
PRISM 377 DNA Sequencer; Applied Biosystems, Foster City, CA).
Luciferase assays. 7 × 104 cells /well (seeded in 24-well plates) were 
transduced with Ad-SV40(Luc 5), Ad-SV40(Luc 5/3), Ad-F512(Luc 5), 
or Ad-F512(Luc 5/3), at 25 × 106 v.p./ml in 200 μl of 2% DMEM/F12. 
Luciferase expression was assessed as described.22
Preparation and use of human tissue explants. Human primary ovarian 
tumor samples were obtained from the Division of Gynecologic Oncology, 
Department of Obstetrics and Gynecology, University of Alabama at 
Birmingham, Birmingham, AL and from the Hospital Municipal de Oncología 
Marie Curie, Buenos Aires, Argentina. Institutional review board approval 
was obtained at the time of initial debulking from patients with histologi-
cally confirmed ovarian adenocarcinoma or nonmalignant ovary samples. 
The declaration of Helsinki protocols were followed and patients gave written 
informed consent. Samples were kept on ice in University of Wisconsin (UW) 
solution (ViaSpan; Barr Laboratories, Pomona, NY) until slicing or alterna-
tively in RPMI medium (Invitrogen, Carlsbad, CA). Time from harvest to 
slicing was kept at an absolute minimum (<2 hours). The Krumdieck tissue 
slicing system (Alabama Research and Development, Birmingham, AL) was 
used in accordance with the manufacturer’s instructions and previously pub-
lished techniques;35 in few cases samples were sliced manually. Viral infections 
were performed with a MOI of 500 in 500 μl of 2% vol/vol FCS RPMI with 
1% antibiotics, 1% L-glutamine into 24-well plates.35 Infections were allowed 
to proceed for 5 hours (E4 assay) or 24 hours (luciferase assay), and then the 
medium was removed and replaced with 10% vol/vol FCS RPMI.
Luciferase assays: Infected tissue slices were placed in cell culture lysis 
buffer (Promega, Madison, WI) with beads and homogenized with an ultra 
sonicator (Fisher Scientific Model 100, Pittsburgh, PA) at a setting of 15 
watts for 10 seconds. The homogenate was centrifuged to pellet the debris, 
and luciferase activity was measured as described.22 Experiments were 
performed in triplicate. Protein concentration of the tissue homogenates 
was determined using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, 
CA) to allow normalization of luciferase expression.
Assessment of virus replication: DNA purification from infected 
tissue slices and qPCR for E4 was performed as described44 with slight 
differences since we selected 72 hours as the end of the experiment 
because we observed no decrease in explants viability up to 96 hours in 
culture (data not shown). Briefly, DNA was purified with the DNeasy 
Tissue kit (Qiagen, Santa Clarita, CA) or Genomic DNA extraction kit 
tissue (Real Genomics, RBC, Taiwan). The primers used for amplification 
of the E4 were forward E4Fuab (Supplementary Table S4) and reverse 
E4Ruab (Supplementary Table S4) and detected with a E4 probe 
(Supplementary Table S4).45 Negative controls without template were 
performed for each reaction series, and an internal control (human 
β-actin) or total DNA were used to normalize the copy number for the 
E4 gene. Comparison of replication rates of different treatment groups 
were performed with a Student’s t-test.
In vitro cytotoxicity assay. For determination of virus-mediated cytotox-
icity, 1 × 104 cells were seeded in 24-well tissue culture plates and infected 
with the CRAds at indicated titers.22 After 6 days, cell viability was mea-
sured using the CellTiter 96 AQueous One Solution Cell Proliferation 
Assay (MTS assay; Promega).
ex vivo replication of CRAds in tumors obtained from nude mice. Five to 
six-weeks-old female athymic N:NIH(S)-nu mice (obtained from Instituto 
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Leloir Facility or from the animal facility of the Faculty of Veterinary, 
University of La Plata, Argentina) were subcutaneous injected in one flank 
either with 3 × 106 SKOV3-luc cells or 4 × 106 PA-1 cells to produce an 
homogeneous ovary tumor or a mix of 3 × 106 or 4 × 106 SKOV3-luc or 
PA-1 cells respectively, mixed with 1 × 106 HMEC-1 and 1 × 106 WI-38 
fibroblasts in 200 μl of PBS to produce an heterogeneous tumors made 
of malignant and stromal cells. When the average tumor volume reached 
500 mm3, mice were sacrificed and the tumors were sliced and infected in 
vitro as described previously for patient samples.
In vivo studies. The i.p. tumors were established by injecting 3 × 106 
SKOV3-luc cells/200 μl into female nude mice (n = 4–5 /group). On day 
7 when the tumor is already established (Supplementary Figure S10), 
5 × 1010 v.p. of AdF512v1 or vehicle were injected i.p. in 400 μl of PBS. 
Imaging was performed before treatment on day -1 and then at days 9, 23, 
and 30 after adenovirus injection with anesthetized animals injected with 
150 mg/kg of D-luciferin i.p. After 10 minutes, the bioluminescent images 
were collected with a CCD, using the IVIS Imaging System (Xenogen, 
Alameda, CA), with the field of view set at 25-cm height. The photographic 
images used a 0.2-second exposure, 8 f/stop, 2 binning (resolution), and 
open filter. The bioluminescent and gray-scale images were overlaid using 
LivingImage software (Xenogen). Regions of interest were drawn around 
the i. p tumors, and the total counts (photons) were summed in the entire 
tumor areas. None of the mice showed signs of wasting or other visible 
indications of toxicity and all animals under study received food and 
water ad-libitum. For studies on viral distribution, 5–6-weeks-old athymic 
N:NIH(S)-nu female mice were injected i.p. with 5 × 1010 v.p./400 μl of 
Ad-F512(Luc 5/3). After 48 hours mice were sacrificed and livers, spleens, 
gonads, kidneys, lungs, stomachs, hearts, and intestines were harvested. 
Organ sections were used to evaluate the luciferase activity as we described 
for tumor samples. To establish viral clearance 5–6-weeks-old athymic 
N:NIH(S)-nu female mice were injected i.p. with 3 × 106 SKOV3-luc 
cells /200 μl. Ten days later mice were injected once with AdF512v1 
(5 × 1010 v.p./400 μl); groups of 2–3 mice were sacrificed at the indicated 
times for tissue isolation. E4 levels were assessed as describe above.
Five to six-weeks-old female nude mice were subcutaneous injected 
either with tumor cells alone or with a mix of tumor cells and stromal 
cells (SKOV3-luc (3 × 106); WI-38 (1 × 106); HMEC-1 (1 × 106)). The in 
vivo treatment started when the average tumor volume reached 100 mm3; 
mice were randomly separated in groups that received three intratumoral 
injections of 1 × 1010 viral particles/mouse of either Ad-F512 or AdF512v1 
on days 0, 3, and 7. Tumor volumes were estimated weekly from caliper 
measurements (volume = 0.5 × (width)2 × length). Mice were sacrificed 
when tumors reached an average of 2,500 mm3. None of the mice showed 
signs of wasting or other visible indications of toxicity.
Ethics statement. All experiments were approved by the Institutional 
Animal Care and Use Committee of the Fundación Instituto Leloir 
(Protocol #30OP). The Fundación Instituto Leloir has an approved Animal 
Welfare Assurance as a foreign institution with the Office of Laboratory 
Animal Welfare, Number A5168-01.
SPARC mRNA quantification. Quantification was performed as previously 
described22.
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